Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia - Wikidata - wikimedia - TriplyDB

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia

http://www.wikidata.org/entity/Q21260279

about

sameAs

Risperidone versus other atypical antipsychotics for schizophrenia Clozapine versus other atypical antipsychotics for schizophrenia Olanzapine versus other atypical antipsychotics for schizophrenia Ziprasidone versus other atypical antipsychotics for schizophrenia Quetiapine versus other atypical antipsychotics for schizophrenia Review of depot aripiprazole for schizophrenia Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs Development of and recovery from difficulty with activities of daily living: an analysis of national data.Predictors of switching antipsychotic medications in the treatment of schizophrenia Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009.Factors associated with antipsychotic medication adherence in community-based patients with schizophrenia in Hong Kong: a cross sectional study.Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence.Health care resource utilization and direct medical costs for patients with schizophrenia initiating treatment with atypical versus typical antipsychotics in Tianjin, China.The 3-year clinical and functional course of schizophrenia among individuals with and without diabetes at study entry Two-year rehospitalization rates of patients with newly diagnosed or chronic schizophrenia on atypical or typical antipsychotic drugs: retrospective cohort study.Effectiveness of sulpiride in adult patients with schizophrenia.Are second generation antipsychotics a distinct class?Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder.Times to Discontinue Antidepressants Over 6 Months in Patients with Major Depressive Disorder Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia.Effectiveness studies: advantages and disadvantages.Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties.Antipsychotic medication-induced dysphoria: its meaning, association with typical vs. atypical medications and impact on adherence.National changes in oral antipsychotic treatment for people with schizophrenia in primary care between 1998 and 2007 in the United Kingdom.Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization.Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example.Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation.Comparing effectiveness of risperidone with first-generation antipsychotic medications in patients with schizophrenia-spectrum disorders.The prescribing pattern of a new antipsychotic: a descriptive study of aripiprazole for psychiatric in-patients.Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia.Persistence with pharmacological treatment in the specialist mental healthcare of patients with severe mental disorders.Pd-Catalyzed double N-arylation of primary amines to synthesize phenoxazines and phenothiazines.Clozapine-Induced Cardiovascular Side Effects and Autonomic Dysfunction: A Systematic Review.

P2860

Q24234950-F6457208-DF0F-4A01-AE04-9E738D339B6A Q24236422-B5AA32A7-59C9-4A40-B583-271A8ED7E348 Q24236545-4361D24F-9503-4CF4-B552-C4CFA23D9127 Q24240260-D4C25EC3-185A-47B2-A074-A0757FE35039 Q24240989-D9914E70-B4C4-41F7-A022-55DCE390EEF4 Q27008464-8A11FCF5-4A16-4C41-8273-54EB2F3BACA5 Q28085407-8843C41F-ECD5-404E-820D-0A9D0C24A718 Q33641065-021DDE71-6ED9-423E-9989-AEDE6D4CC3F6 Q33709704-8A048399-E74A-4917-AEFF-8A1B4906CAB2 Q33903511-1436C3DA-8D56-4F78-9F75-25CCB53BD65F Q34098311-5808BED4-CB74-4910-83CF-F1119FD0B196 Q34318836-E025A73E-EE24-4E9D-BFDE-76A79F44B374 Q34502693-08ECD8D3-43D7-4725-8C35-2DD9F1E12180 Q35018988-D388574C-6E6A-461F-BE55-799C8AD93AD0 Q35568945-FC63EC21-9A28-44C7-8824-0CB507E7D3E8 Q35851083-4712C4EA-FA0B-4456-9974-CE3E601349F4 Q36609365-CFF6B9CC-157B-4A0B-AC15-BA9F2C10FEA4 Q36770037-2753F15B-0078-41B5-87CB-C05E686A25F5 Q36784527-2F6BDADC-D09C-438A-A4F6-5225041C308B Q37052769-F709823E-528A-4866-A1D9-EFB60E90EE60 Q37136995-12E075EC-6C24-48E6-B654-642AC7D62DC9 Q37185914-1F7A2476-3D56-42DA-BF4B-E30677DB5750 Q37405519-55B0EC3A-4E8F-4EBC-ABC1-4F8FCDFAA2A5 Q37917728-79CD829D-D545-47CE-BDB5-891880D889E4 Q37985887-4B6E7FA8-168B-483E-9351-96AD0515CB97 Q38244017-2DA1E2A2-8C02-4468-93A7-16E7CF6AF9AC Q38437417-83A161B4-9A9B-4FC1-B459-7C58F9535CE9 Q40427460-1A4B7826-3939-47A0-9F20-0890426406F4 Q40501293-36D8BD7C-8BA2-42D6-BD0D-6B1644FC79AA Q41449760-5C1EC8F9-1E27-44F3-BCB9-B7E2CBFF62AA Q42264057-D3028DA4-8595-4A0C-A8C7-6CE5C4527A89 Q43228765-DF1C0AEB-035F-40AD-AAC2-3048B6BE164B Q44243570-B0DFB794-F067-4073-87A7-6A733C13E9D7 Q44673143-1D87BA97-C1FD-47C0-86C9-838D43B43E01 Q47785684-E4AED0B1-6C7C-44E3-8439-68CA44B60DBD Q47915791-56B6CD65-73C8-4C1C-AE0F-68046D7EC2D6 Q52579281-66CB9EE7-0D2B-42CE-8AF8-19086A36155E

P2860

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia

http://www.wikidata.org/entity/Q21260279

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Time to discontinuation of aty ...... tic treatment of schizophrenia

@ast

Time to discontinuation of aty ...... tic treatment of schizophrenia

@en

Time to discontinuation of aty ...... tic treatment of schizophrenia

@en-gb

Time to discontinuation of aty ...... tic treatment of schizophrenia

@nl

type

label

Time to discontinuation of aty ...... tic treatment of schizophrenia

@ast

Time to discontinuation of aty ...... tic treatment of schizophrenia

@en

Time to discontinuation of aty ...... tic treatment of schizophrenia

@en-gb

Time to discontinuation of aty ...... tic treatment of schizophrenia

@nl

prefLabel

Time to discontinuation of aty ...... tic treatment of schizophrenia

@ast

Time to discontinuation of aty ...... tic treatment of schizophrenia

@en

Time to discontinuation of aty ...... tic treatment of schizophrenia

@en-gb

Time to discontinuation of aty ...... tic treatment of schizophrenia

@nl

P1433

Q21260279-E94F208D-8B40-4429-84C0-6A5464A3C2A4

P1476

Q21260279-8FCDEA87-0191-46AD-A80A-61F6CE3CD9AC

P2093

Q21260279-04D351CC-3A0C-42CE-A35C-A125D1D4BA1F

Q21260279-2E18C793-82D8-4DAB-9973-A561C652D9C2

Q21260279-3D915870-5174-405B-BC86-81750CE70E5B

Q21260279-B76BF6A8-4056-4806-8840-D0FB4150E8AA

Q21260279-CFA6B081-636B-4F83-ADBC-11A0539FEAC5

P2860

Q21260279-0127AAE0-C648-48B2-89D4-1BEFED37A3F0

Q21260279-12683B25-0CDA-4A63-94D0-7FA5D3D27AF8

Q21260279-13619708-8B45-432B-B5A4-471D0F3A1FA1

Q21260279-2A2CAA1B-E09C-4773-9DCE-FAA539858D72

Q21260279-3606655E-9B3B-40D9-B6A1-0CCCBFE5D51A

Q21260279-3C6D8F3A-2BC6-4045-AF5A-50309A121C30

Q21260279-3D58C9F2-1A64-42C1-88FA-BDA964F450F5

Q21260279-43B8044A-E2DC-4D30-AB55-3BC1FE661216

Q21260279-445A1426-ADD2-4862-B154-D563741ED150

Q21260279-47611770-E29E-436D-9A7A-E0A6B85ABDD9

P2888

Q21260279-383AC378-1B83-47C7-B365-3A10ED550C4E

P304

Q21260279-643234C2-6C04-4FE1-8C07-2E2456D581D8

P31

Q21260279-28C8A53E-DFDE-4122-A97F-E390E129D12B

P3181

Q21260279-24FF299E-DF5E-4737-8C1B-78960C6CD64F

P356

Q21260279-861AC7B5-6C8D-468A-BB92-8CE39D0C58B4

P407

Q21260279-A19C7D01-6AA5-46E4-B802-F0F8833AD5FF

P433

Q21260279-017F9DE3-B800-4A46-89E9-ECA9546BA83C

P478

Q21260279-45D18A5F-C6CE-4520-87D5-343DBA633691

P50

Q21260279-7FFFCEB6-B590-4A91-9827-F691315CDEB1

P577

Q21260279-3ACFFFF4-90E4-4EFC-B167-9FEB379DDD07

P6179

Q21260279-E183A29A-989A-42AE-B518-A1BA31883625

P698

Q21260279-0B5AA54B-8023-4690-B6E8-FC33E8914451

P921

Q21260279-596D1A4B-D526-457A-819B-FEFDD2895CAA

P932

Q21260279-919A2B3A-0F3E-4792-A99C-B66971960912

P3181

P356

P1433

P1476

Time to discontinuation of aty ...... tic treatment of schizophrenia

@en

P2093

Baojin Zhu

http://www.w3.org/2001/XMLSchema#string

Douglas Faries

http://www.w3.org/2001/XMLSchema#string

Jeff Swanson

http://www.w3.org/2001/XMLSchema#string

Marvin Swartz

http://www.w3.org/2001/XMLSchema#string

Ron Landbloom

http://www.w3.org/2001/XMLSchema#string

P2860

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics

Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs.

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

Using drug claims data to assess the relationship of medication adherence with hospitalization and costs.

Dropout rates in randomised antipsychotic drug trials.

Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission.

Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.

Effect of mental health specialty care on antidepressant length of therapy.

P2888

P304

8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4415419

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/1471-244X-6-8

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Haya Ascher-Svanum

P577

2006-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1008909132

http://www.w3.org/2001/XMLSchema#string

P698

16504026

http://www.w3.org/2001/XMLSchema#string

P921

P932

1402287

http://www.w3.org/2001/XMLSchema#string